At Cellectricon, we create new avenues for neuroscience drug discovery. Our mission is to create groundbreaking concepts that will advance the neuroscience research field. From early concept evaluation to transformative drug discovery campaigns, we solve your scientific challenges through innovative approaches for in vitro research. We help you to: • Obtain new insights into disease biology • Accelerate the R&D process and reduce time to decision-making • Identify targets and lead compounds with potential to produce first-in-class medicines Our unique discovery platform combines drug discovery expertise and disease area knowledge with cutting-edge technologies. With the platform, we create complex disease models and assays for functional and morphological screening. We have established service modules in the areas of Peripheral Neuropathies, Neurodegeneration and Neuroplasticity. Through our services, we can accelerate your target and lead discovery programs.
View Top Employees from CellectriconWebsite | https://www.cellectricon.com |
Revenue | $34 million |
Employees | 23 (13 on RocketReach) |
Founded | 2001 |
Phone | (301) 926-9264 |
Technologies |
JavaScript,
HTML,
Twitter
+23 more
(view full list)
|
Industry | Biotechnology, Business Services General, Medical, Cellular screening technologies, Business Services, Health Care, High-throughput transfection, Intra-cellular target screening, Field stimulation and voltage control assays, Adherent cell electroporation, Ion Channel Research Products, Discovery Services |
SIC | SIC Code 87 Companies, SIC Code 873 Companies |
NAICS | NAICS Code 54 Companies, NAICS Code 541714 Companies, NAICS Code 5417 Companies, NAICS Code 54171 Companies, NAICS Code 541 Companies |
Looking for a particular Cellectricon employee's phone or email?
The Cellectricon annual revenue was $34 million in 2024.
Mattias Karlsson is the CEO of Cellectricon.
13 people are employed at Cellectricon.
The NAICS codes for Cellectricon are [54, 541714, 5417, 54171, 541].
The SIC codes for Cellectricon are [87, 873].